Does the media refer more to PTGX or BIIB?

In the previous week, Biogen had 19 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 28 mentions for Biogen and 9 mentions for Protagonist Therapeutics. Biogen's average media sentiment score of 1.33 beat Protagonist Therapeutics' score of 0.96 indicating that Biogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protagonist Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biogen 22 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ALNY or PTGX?

In the previous week, Alnylam Pharmaceuticals had 16 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 25 mentions for Alnylam Pharmaceuticals and 9 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 0.96 beat Alnylam Pharmaceuticals' score of 0.78 indicating that Protagonist Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 11 Very Positive mention(s) 1 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Protagonist Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ROIV or PTGX?

In the previous week, Roivant Sciences had 10 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 19 mentions for Roivant Sciences and 9 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 0.96 beat Roivant Sciences' score of 0.48 indicating that Protagonist Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 10 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Protagonist Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to PTGX or MRNA?

In the previous week, Moderna had 104 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 113 mentions for Moderna and 9 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 0.96 beat Moderna's score of 0.40 indicating that Protagonist Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protagonist Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Moderna 46 Very Positive mention(s) 16 Positive mention(s) 14 Neutral mention(s) 18 Negative mention(s) 14 Very Negative mention(s) Neutral

Protagonist Therapeutics (PTGX) Competitors

$154.32 +3.63 (+2.41%)

As of 08/21/2026 04:00 PM Eastern

Compare

PTGX vs. BIIB, ALNY, INSM, ROIV, and MRNA

Should you buy Protagonist Therapeutics stock or one of its competitors? Protagonist Therapeutics's main competitors and comparable companies include Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), Insmed (INSM), Roivant Sciences (ROIV), and Moderna (MRNA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Protagonist Therapeutics compare to Biogen?

Protagonist Therapeutics (NASDAQ:PTGX) and Biogen (NASDAQ:BIIB) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Biogen has higher revenue and earnings than Protagonist Therapeutics. Biogen is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$46.02M	216.99	-$130.15M	$1.03	149.83
Biogen	$10.03B	3.19	$1.29B	$5.65	38.37

Protagonist Therapeutics has a beta of 1.78, meaning that its share price is 78% more volatile than the broader market. Comparatively, Biogen has a beta of 0.17, meaning that its share price is 83% less volatile than the broader market.

98.6% of Protagonist Therapeutics shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 5.2% of Protagonist Therapeutics shares are owned by insiders. Comparatively, 0.3% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Protagonist Therapeutics has a net margin of 29.40% compared to Biogen's net margin of 8.32%. Protagonist Therapeutics' return on equity of 12.03% beat Biogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	29.40%	12.03%	11.23%
Biogen	8.32%	11.18%	6.88%

Protagonist Therapeutics currently has a consensus price target of $140.53, suggesting a potential downside of 8.93%. Biogen has a consensus price target of $227.07, suggesting a potential upside of 4.75%. Given Biogen's higher possible upside, analysts plainly believe Biogen is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	0 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.94
Biogen	1 Sell rating(s)	13 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.58

In the previous week, Biogen had 19 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 28 mentions for Biogen and 9 mentions for Protagonist Therapeutics. Biogen's average media sentiment score of 1.33 beat Protagonist Therapeutics' score of 0.96 indicating that Biogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protagonist Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biogen	22 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Protagonist Therapeutics beats Biogen on 9 of the 16 factors compared between the two stocks.

How does Protagonist Therapeutics compare to Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Protagonist Therapeutics (NASDAQ:PTGX) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability.

In the previous week, Alnylam Pharmaceuticals had 16 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 25 mentions for Alnylam Pharmaceuticals and 9 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 0.96 beat Alnylam Pharmaceuticals' score of 0.78 indicating that Protagonist Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	11 Very Positive mention(s)	1 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Protagonist Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alnylam Pharmaceuticals has a beta of 0.3, indicating that its stock price is 70% less volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.78, indicating that its stock price is 78% more volatile than the broader market.

Alnylam Pharmaceuticals currently has a consensus price target of $386.62, suggesting a potential upside of 63.67%. Protagonist Therapeutics has a consensus price target of $140.53, suggesting a potential downside of 8.93%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Alnylam Pharmaceuticals is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	15 Buy rating(s)	4 Strong Buy rating(s)	2.96
Protagonist Therapeutics	0 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.94

Alnylam Pharmaceuticals has higher revenue and earnings than Protagonist Therapeutics. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$4.80B	6.58	$313.75M	$5.38	43.91
Protagonist Therapeutics	$46.02M	216.99	-$130.15M	$1.03	149.83

93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are held by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are held by company insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Protagonist Therapeutics has a net margin of 29.40% compared to Alnylam Pharmaceuticals' net margin of 15.26%. Alnylam Pharmaceuticals' return on equity of 84.93% beat Protagonist Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%
Protagonist Therapeutics	29.40%	12.03%	11.23%

Summary

Alnylam Pharmaceuticals beats Protagonist Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Protagonist Therapeutics compare to Insmed?

Protagonist Therapeutics (NASDAQ:PTGX) and Insmed (NASDAQ:INSM) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends.

Protagonist Therapeutics has a beta of 1.78, indicating that its stock price is 78% more volatile than the broader market. Comparatively, Insmed has a beta of 0.81, indicating that its stock price is 19% less volatile than the broader market.

Protagonist Therapeutics has higher earnings, but lower revenue than Insmed. Insmed is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$46.02M	216.99	-$130.15M	$1.03	149.83
Insmed	$606.42M	45.29	-$1.28B	-$4.11	N/A

98.6% of Protagonist Therapeutics shares are owned by institutional investors. 5.2% of Protagonist Therapeutics shares are owned by insiders. Comparatively, 2.1% of Insmed shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Protagonist Therapeutics has a net margin of 29.40% compared to Insmed's net margin of -76.94%. Protagonist Therapeutics' return on equity of 12.03% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	29.40%	12.03%	11.23%
Insmed	-76.94%	-123.94%	-44.30%

In the previous week, Protagonist Therapeutics had 9 more articles in the media than Insmed. MarketBeat recorded 9 mentions for Protagonist Therapeutics and 0 mentions for Insmed. Insmed's average media sentiment score of 1.44 beat Protagonist Therapeutics' score of 0.96 indicating that Insmed is being referred to more favorably in the news media.

Company	Overall Sentiment
Protagonist Therapeutics	Positive
Insmed	Positive

Protagonist Therapeutics currently has a consensus price target of $140.53, suggesting a potential downside of 8.93%. Insmed has a consensus price target of $205.52, suggesting a potential upside of 63.41%. Given Insmed's stronger consensus rating and higher probable upside, analysts clearly believe Insmed is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	0 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.94
Insmed	1 Sell rating(s)	0 Hold rating(s)	22 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Protagonist Therapeutics beats Insmed on 11 of the 17 factors compared between the two stocks.

How does Protagonist Therapeutics compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and Protagonist Therapeutics (NASDAQ:PTGX) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, media sentiment, institutional ownership and valuation.

Protagonist Therapeutics has a net margin of 29.40% compared to Roivant Sciences' net margin of -3,534.96%. Protagonist Therapeutics' return on equity of 12.03% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,534.96%	-22.94%	-21.53%
Protagonist Therapeutics	29.40%	12.03%	11.23%

In the previous week, Roivant Sciences had 10 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 19 mentions for Roivant Sciences and 9 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 0.96 beat Roivant Sciences' score of 0.48 indicating that Protagonist Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	10 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Protagonist Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Protagonist Therapeutics has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	3,174.36	-$299.77M	-$0.53	N/A
Protagonist Therapeutics	$46.02M	216.99	-$130.15M	$1.03	149.83

64.8% of Roivant Sciences shares are owned by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are owned by institutional investors. 8.8% of Roivant Sciences shares are owned by insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Roivant Sciences has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.78, meaning that its share price is 78% more volatile than the broader market.

Roivant Sciences presently has a consensus price target of $35.14, indicating a potential downside of 3.21%. Protagonist Therapeutics has a consensus price target of $140.53, indicating a potential downside of 8.93%. Given Roivant Sciences' higher probable upside, equities research analysts plainly believe Roivant Sciences is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Protagonist Therapeutics	0 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.94

Summary

Protagonist Therapeutics beats Roivant Sciences on 12 of the 16 factors compared between the two stocks.

How does Protagonist Therapeutics compare to Moderna?

Protagonist Therapeutics (NASDAQ:PTGX) and Moderna (NASDAQ:MRNA) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, profitability, risk, dividends, earnings and analyst recommendations.

98.6% of Protagonist Therapeutics shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 5.2% of Protagonist Therapeutics shares are owned by insiders. Comparatively, 10.8% of Moderna shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Protagonist Therapeutics has a net margin of 29.40% compared to Moderna's net margin of -141.43%. Protagonist Therapeutics' return on equity of 12.03% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	29.40%	12.03%	11.23%
Moderna	-141.43%	-28.30%	-19.39%

In the previous week, Moderna had 104 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 113 mentions for Moderna and 9 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 0.96 beat Moderna's score of 0.40 indicating that Protagonist Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protagonist Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Moderna	46 Very Positive mention(s)	16 Positive mention(s)	14 Neutral mention(s)	18 Negative mention(s)	14 Very Negative mention(s)	Neutral

Protagonist Therapeutics has a beta of 1.78, suggesting that its share price is 78% more volatile than the broader market. Comparatively, Moderna has a beta of 0.91, suggesting that its share price is 9% less volatile than the broader market.

Protagonist Therapeutics presently has a consensus target price of $140.53, indicating a potential downside of 8.93%. Moderna has a consensus target price of $69.50, indicating a potential downside of 52.09%. Given Protagonist Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Protagonist Therapeutics is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	0 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.94
Moderna	4 Sell rating(s)	11 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.00

Protagonist Therapeutics has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$46.02M	216.99	-$130.15M	$1.03	149.83
Moderna	$1.94B	29.79	-$2.82B	-$7.99	N/A

Summary

Protagonist Therapeutics beats Moderna on 14 of the 17 factors compared between the two stocks.

Get Protagonist Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PTGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PTGX vs. The Competition

Export

Metric	Protagonist Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$9.99B	$4.01B	$7.37B	$12.85B
Dividend Yield	N/A	3.64%	2.53%	11.08%
P/E Ratio	149.83	11.62	272.60	24.25
Price / Sales	216.99	1,334.62	624.33	101.47
Price / Cash	N/A	105.14	78.62	53.99
Price / Book	11.86	16.80	13.05	6.20
Net Income	-$130.15M	-$12.50M	$3.47B	$348.59M
7 Day Performance	-0.50%	3.29%	2.09%	0.08%
1 Month Performance	13.95%	8.23%	6.64%	3.88%
1 Year Performance	168.48%	55.05%	25.02%	16.98%

Protagonist Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PTGX Protagonist Therapeutics	2.0026 of 5 stars	$154.32 +2.4%	$140.53 -8.9%	+168.5%	$9.99B	$46.02M	149.83	120	Analyst Upgrade
BIIB Biogen	3.9575 of 5 stars	$209.83 -0.4%	$227.07 +8.2%	+55.6%	$31.12B	$9.89B	37.14	7,500	News Coverage Positive News
ALNY Alnylam Pharmaceuticals	4.9356 of 5 stars	$228.65 +0.7%	$393.86 +72.3%	-48.0%	$30.39B	$3.71B	42.50	2,770	News Coverage Analyst Upgrade
INSM Insmed	3.4485 of 5 stars	$123.74 -2.1%	$205.52 +66.1%	-4.6%	$27.59B	$606.42M	N/A	1,664	Positive News
ROIV Roivant Sciences	1.5285 of 5 stars	$36.20 -0.2%	$35.14 -2.9%	+204.5%	$26.10B	$8.26M	N/A	860	Analyst Forecast Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PTGX) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Protagonist Therapeutics (PTGX) Competitors

PTGX vs. BIIB, ALNY, INSM, ROIV, and MRNA

How does Protagonist Therapeutics compare to Biogen?

Summary

How does Protagonist Therapeutics compare to Alnylam Pharmaceuticals?

Summary

How does Protagonist Therapeutics compare to Insmed?

Summary

How does Protagonist Therapeutics compare to Roivant Sciences?

Summary

How does Protagonist Therapeutics compare to Moderna?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTGX vs. The Competition

Protagonist Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Protagonist Therapeutics (PTGX) Competitors

PTGX vs. BIIB, ALNY, INSM, ROIV, and MRNA

How does Protagonist Therapeutics compare to Biogen?

Which has higher earnings & valuation, PTGX or BIIB?

Which has more volatility & risk, PTGX or BIIB?

Do insiders and institutionals hold more shares of PTGX or BIIB?

Is PTGX or BIIB more profitable?

Do analysts rate PTGX or BIIB?

Does the media refer more to PTGX or BIIB?

Summary

How does Protagonist Therapeutics compare to Alnylam Pharmaceuticals?

Does the media refer more to ALNY or PTGX?

Which has more risk & volatility, ALNY or PTGX?

Do analysts prefer ALNY or PTGX?

Which has higher earnings and valuation, ALNY or PTGX?

Do insiders & institutionals hold more shares of ALNY or PTGX?

Is ALNY or PTGX more profitable?

Summary

How does Protagonist Therapeutics compare to Insmed?

Which has more risk & volatility, PTGX or INSM?

Which has stronger earnings and valuation, PTGX or INSM?

Do institutionals and insiders hold more shares of PTGX or INSM?

Is PTGX or INSM more profitable?

Does the media prefer PTGX or INSM?

Do analysts rate PTGX or INSM?

Summary

How does Protagonist Therapeutics compare to Roivant Sciences?

Is ROIV or PTGX more profitable?

Does the media favor ROIV or PTGX?

Which has preferable earnings & valuation, ROIV or PTGX?

Do institutionals & insiders have more ownership in ROIV or PTGX?

Which has more risk & volatility, ROIV or PTGX?

Do analysts prefer ROIV or PTGX?

Summary

How does Protagonist Therapeutics compare to Moderna?

Do insiders and institutionals believe in PTGX or MRNA?

Is PTGX or MRNA more profitable?

Does the media refer more to PTGX or MRNA?

Which has more volatility and risk, PTGX or MRNA?

Do analysts recommend PTGX or MRNA?

Which has better earnings and valuation, PTGX or MRNA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTGX vs. The Competition

Protagonist Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools